Home
NICE announces more people eligible for nusinersen following review of Managed Access Agreement
NICE has today (4 May 2021) announced that more people with the rare genetic disorder spinal muscular atrophy (SMA) are to benefit from nusinersen (also called Spinraza and made by Biogen) following a review of data collected as part of the Managed Access Agreement (MAA).
04 May 2021
The review, involving Biogen, patient groups, clinicians, SMA REACH UK and NHS England and NHS Improvement, assessed whether new evidence that had become available would support a change in the MAA treatment eligibility criteria. Specifically, it looked at whether people with type III SMA who are unable to walk can benefit from nusinersen and therefore should be included in the MAA.
Daiichi Sankyo’s cholesterol-lowering drugs recommended for NHS use
29th April 2021
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Daiichi Sankyo’s cholesterol drugs Nilemdo and Nustendi for use on the NHS, benefitting around 70,000 adults in England with high cholesterol.
NICE has recommended the use of Nilemdo (bempedoic acid) with ezetimibe or in the fixed-dose combination form – Nustendi.
Patients with primary hypercholesterolaemia or mixed dyslipidemia – high cholesterol – will be offered treatment with bempedoic acid with ezetimibe when statins cannot be taken or have not worked.
The current treatment for these patients includes dietary changes aimed at lowering low-density lipoprotein cholesterol (LDL-C) levels.
First new oral treatment for high cholesterol in a decade approved by NICE
Bempedoic acid has been approved for routine NHS prescribing with ezetimibe to treat primary hypercholesterolaemia or mixed dyslipidaemia when statins are unsuitable.
by Chloe Harman
Sign in to continue
Free email bulletins
NICE recommends ravulizumab for treatment of a rare blood disorder europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
Sovaldi stumbles as NICE assesses hep C drug s price
Gilead must provide much more cost-effectiveness information
The UK has become the latest country to put the price of Sovaldi under the microscope and Gilead s hepatitis C drug has stumbled at its first hurdle.
In draft guidance the cost-effectiveness watchdog NICE said it was “minded not to recommend” Sovaldi (sofobuvir), adding that it has asked the drug s manufacturer for much more detailed information about its use and cost.
The first all-oral treatment for chronic hep C to be approved in Europe, Sovaldi is taken for an average of 12 or 24 weeks, depending on patient needs, giving it a UK list price of £35,983 (€45,041) or £69,966 (€87,575) for a course of treatment.